Article Text

Download PDFPDF
Pre-endoscopic serological test with duodenal biopsy in high risk patients had high sensitivity and low specificity for coeliac disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q Does a clinical decision tool (CDT) based on pre-endoscopic serological testing with duodenal biopsy for high risk patients accurately diagnose coeliac disease?

Clinical impact ratings Gastroenterology ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆


Embedded ImageDesign:

2 cohort studies, 1 for derivation and 1 for validation.

Embedded ImageSetting:

endoscopy department at the Royal Hallamshire Hospital, Sheffield, UK.

Embedded ImagePatients:

1464 patients in the retrospective derivation cohort and 2000 patients 16–94 years of age (mean age 56 y, 58% women) in the prospective validation cohort who were referred for gastroscopy. Exclusion criteria were previously known coeliac disease, coagulopathy (international normalised ratio >1.3 or platelets <80 x 109/l), active gastrointestinal bleeding, or suspected cancer.

Embedded ImageDescription of prediction guide:

the CDT combined pre-endoscopic serological testing (tissue transglutaminase [TTG] antibody) and assessment of symptoms to identify patients at high or low risk of coeliac disease. The CDT was modified in the validation …

View Full Text


  • For correspondence: Dr A D Hopper, Royal Hallamshire Hospital, United Kingdom. andydhopper{at}

  • Source of funding: no external funding.